Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor Corporation (Nasdaq: DXR) will present at the H.C. Wainwright Global Life Investment Hybrid Conference from May 23-26, 2022, in Miami Beach, FL. CEO Michael Feldschuh will speak on May 25 at 4:30 PM ET, highlighting the company's achievements in financial performance, product commercialization, and collaborations with the U.S. Department of Defense and the National Institute of Health. Daxor's BVA-100® blood test is pivotal in managing critical care, COVID-19, and heart failure, with over 60,000 tests conducted. Interested parties can register for the event and request one-on-one meetings.
Daxor Corporation (Nasdaq: DXR) has presented new data at the ISHLT Annual Meeting showcasing the efficacy of its BVA-100 blood test in enhancing survival rates for advanced heart failure patients using LVADs. The study revealed that 91% of patients with LVADs exhibited abnormal blood volume, indicating the test's critical role in patient management. With a 98% accuracy rate, the BVA-100 test helps identify derangements in blood volume, potentially improving patient outcomes. Daxor emphasizes its commitment to advancing healthcare through blood volume analysis technology.
Daxor Corporation (Nasdaq: DXR) presented new data from a study at the 71st American College of Cardiology meeting on April 2, revealing the effectiveness of the BVA-100 test in measuring intravascular congestion in heart failure patients. This test outperformed common clinical tools, which were found ineffective. The study led by Dr. Vishal N. Rao emphasized that blood volume measurements do not correlate with cardiac pressures, indicating the superiority of Daxor's approach in improving patient outcomes in heart failure management.
Daxor Corporation (Nasdaq: DXR) announced that CEO Michael Feldschuh will present at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. The presentation will cover recent achievements, including contracts with the U.S. Department of Defense, NIH grant funding, and clinical trials for its BVA-100® blood test aimed at critical care management, COVID-19, and heart failure. Registration is required to attend the conference and view the presentation.
Daxor Corporation (Nasdaq: DXR) reported significant achievements in its recent shareholder update. On February 4, 2022, Daxor celebrated its Nasdaq listing with a ceremonial bell ringing in Times Square. The company achieved a 70.6% revenue increase in 2021 compared to the previous year, reporting a net asset value of $21.15 million. Daxor plans to launch new point-of-care blood volume systems in 2022, enhancing market capabilities. The company also made strides in clinical outcomes and research with NIH support, marking a pivotal year for growth and innovation.
Daxor Corporation (Nasdaq: DXR) reported impressive financial results for fiscal 2021, achieving a 70.6% increase in unaudited revenues from its operating division, which includes the BVA diagnostic systems. The company's net asset value (NAV) rose to $5.24 per share, marking a 34.7% increase from $3.89 in 2020. The growth is attributed to new client contracts, including the U.S. Department of Defense. Daxor also announced advancements in its next-generation blood volume analysis technology and secured a $750,000 contract for further development.
Daxor Corporation (Nasdaq: DXR) has revealed new data on the clinical utility of its BVA-100 blood test for heart failure patients, published in the Journal of Cardiac Failure. The study indicates a disconnect between pressure and blood volume metrics, emphasizing the importance of blood volume assessment over pressure monitoring in managing heart failure. Authors noted that volume-based strategies may enhance patient care. With over 100 peer-reviewed studies supporting its efficacy, Daxor's technology is positioned as a critical tool in addressing heart volume management.
Daxor Corporation (Nasdaq: DXR) commenced trading on the NASDAQ Capital Markets on February 2, 2022. To celebrate, CEO Michael Feldschuh will ring the Opening Bell on February 4, 2022. This milestone is expected to enhance the company's visibility, trading liquidity, and attract institutional investors. Daxor specializes in blood volume measurement technology, with over 60,000 tests conducted using their FDA-cleared BVA-100. Ongoing trials in heart failure and COVID-19 are supported by the NIH and the Department of Defense.
Daxor Corporation (NYSE: DXR) has appointed Caleb DesRosiers to its Board of Directors, effective January 18, 2022. DesRosiers, a Senior Principal at Valuate Healthcare Consultancy, brings extensive strategic and regulatory experience to the role, having previously worked with CMS and in the life sciences sector at Pfizer and Roche. CEO Michael Feldschuh expressed that DesRosiers' expertise will support Daxor's vision of optimal blood volume for patients. Daxor is a leader in blood volume measurement technology with its FDA-cleared BVA-100 Blood Volume Analyzer.
Daxor Corporation (NYSE: DXR) has announced the transfer of its common stock listing from the New York Stock Exchange - American to The Nasdaq Capital Market, effective February 2, 2022. CEO Michael Feldschuh stated that this move is expected to enhance stock visibility, trading liquidity, and attract institutional investors. Daxor is recognized for its BVA-100® technology, the first FDA-cleared diagnostic blood test for quantifying blood volume. The company aims to advance healthcare through optimal fluid management.
FAQ
What is the current stock price of Daxor Corporation (DXR)?
What is the market cap of Daxor Corporation (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
